In clinical trials, the first slowed disease progression by 27%, and the second by 35%. They even compare efficacy, cost, and impact of the new Alzheimer’s drugs with those of other biologic drugs for different conditions. Another comparison: the reduction in disability from anti-amyloid drugs in Alzheimer’s is similar to that observed in trials of biologic drugs for rheumatoid arthritis or multiple sclerosis. According to Fortea, in asymptomatic contexts, the only way to select individuals who have Alzheimer’s will also be the biomarker. These are clinical trials that are underway and will be published in 2027.